GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Price-to-Funds-From-Operations

Ultimovacs ASA (OSL:ULTI) Price-to-Funds-From-Operations : (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Ultimovacs ASA (OSL:ULTI) Business Description

Industry
Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.